Peptide Hubs
Peptide Hubs
You will save $24.00
AOD 9604 5 mg
Product Information Compound Details
Active Substance AOD 9604 hGH fragment 177-191
5 mg/vialStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$36.00
$60.00
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
AOD 9604 5 mg by Peptide Hubs
AOD 9604 5 mg is a lyophilized research peptide manufactured by Peptide Hubs and supplied as a 5 mg/vial powder in a 2 mL vial.
AOD 9604 Injectable
AOD 9604 5 mg contains AOD 9604 (also known as AOD9604 or LAT-8881), a synthetic 16-amino-acid peptide fragment corresponding to the C-terminal region of human growth hormone (hGH), specifically residues 177-191 with an additional tyrosine at the N-terminus. This compound was developed by Metabolic Pharmaceuticals in the late 1990s as a potential treatment for obesity, with Phase I and Phase II clinical trials conducted in the early 2000s.
Unlike full-length growth hormone, AOD 9604 does not interact with the hGH receptor and does not stimulate IGF-1 production or affect blood glucose levels. Its proposed mechanism involves direct stimulation of lipolysis and fat oxidation through pathways independent of the traditional hGH receptor, potentially involving beta-3 adrenergic receptor-like signaling. This selective activity has made it a subject of interest in non-medical bodybuilding contexts for fat-loss applications.
Despite promising preclinical data, AOD 9604 failed to achieve statistically significant weight loss in its pivotal Phase IIb clinical trial, and development was discontinued. The compound is not FDA-approved as a drug, and the FDA has evaluated AOD 9604-related bulk drug substances for compounding and found that available safety data is insufficient.
Key Benefits of AOD 9604 5 mg
- hGH fragment 177-191 with proposed lipolytic activity
- Lyophilized powder format for reconstitution flexibility
- Does not stimulate IGF-1 or affect blood glucose in studied doses
- Commonly referenced for fat oxidation research contexts
- Manufactured by Peptide Hubs
Formulation
Lyophilized Powder
AOD 9604 5 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. Reconstitution with an appropriate solvent is required before use in research contexts.
Product Profile
AOD 9604 Profile
AOD 9604 is a synthetic hexadecapeptide with a molecular weight of approximately 1,815 Da. Its structure consists of the C-terminal fragment of human growth hormone (residues 177-191) with an N-terminal tyrosine extension and a disulfide bond between cysteine residues.
hGH Fragment Peptide
AOD 9604 belongs to the class of growth hormone fragment peptides, which are synthetic derivatives of specific hGH regions rather than full-length hormone analogs. Unlike growth hormone secretagogues such as ipamorelin or sermorelin, which stimulate endogenous GH release, AOD 9604 is a fragment of the GH molecule itself and does not act on the hGH receptor.
Preclinical research in obese mice demonstrated that AOD 9604 reduced body weight gain, increased fat oxidation, and stimulated lipolysis—effects comparable to full-length hGH but without the hyperglycemia or insulin suppression associated with hGH treatment. The peptide's short half-life of approximately 30 minutes following subcutaneous administration supports once-daily dosing in research protocols.
In non-medical bodybuilding contexts, AOD 9604 is commonly referenced for localized fat reduction and lipolytic support, particularly in fasted states or before cardiovascular exercise. However, the pivotal Phase IIb clinical trial (OPTIONS study) failed to demonstrate statistically significant weight loss, and the compound is not approved for any human indication.
Defining Characteristic
hGH Fragment with Selective Activity
AOD 9604 is distinguished by its selectivity: it retains the lipolytic effects observed with full-length growth hormone while lacking the IGF-1 stimulation and glucose effects that limit hGH use. This selectivity is the basis for its investigation as a metabolic research compound.
AOD 9604 5 mg vs Other Peptide Hubs Preparations
Peptide Hubs offers a range of research peptides targeting different aspects of metabolic and endocrine biology. Within this lineup, Adipotide (FTPP) is commonly discussed alongside AOD 9604 for fat-loss research, though adipotide operates through vascular targeting and apoptosis induction rather than lipolytic signaling. The two compounds carry fundamentally different mechanisms and risk profiles.
For research focused on growth hormone stimulation rather than GH fragment activity, Sermorelin represents a different approach, acting as a GHRH analog to stimulate endogenous GH release. These peptides are not interchangeable and target distinct biological pathways.
Dosage & Usage
AOD 9604 5 mg Dosage & Usage
The information below is provided for educational reference only. AOD 9604 is not FDA-approved as a drug. Its use for any non-medical purpose falls outside approved indications, and no established human dosing regimen exists for injectable administration.
Typical Dosage Ranges
Human clinical trials conducted by Metabolic Pharmaceuticals used oral AOD 9604 at 1 mg per day, administered over 12-24 weeks. The injectable form, while not used in published human trials, is commonly referenced in research communities at 250-500 mcg per day subcutaneously.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Clinical trial (oral, not injectable) | 1 mg per day | Once daily, fasted |
| Research protocol (subcutaneous) | 250-500 mcg per day | Once daily, fasted morning |
| Community protocol (anecdotal) | 300 mcg per day | Once daily, pre-exercise |
These injectable ranges are community conventions and have not been validated in published human clinical trials. The oral and subcutaneous dose ranges are not interchangeable due to differences in bioavailability.
Reconstitution & Handling
AOD 9604 5 mg is supplied as a lyophilized powder and requires reconstitution before use. A common ratio is 2 mL of bacteriostatic water into a 5 mg vial, yielding a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1 mL on a U-100 insulin syringe.
Reconstituted solution should be stored refrigerated at 2-8°C and used within 28 days. Freeze-thaw cycles should be avoided as they may degrade peptide structure.
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, AOD 9604 is sometimes combined with GLP-1 receptor agonists or other metabolic compounds. Some users reference stacking with MOTS-C for complementary metabolic effects, though this represents an unstudied combination.
Clinical trials ran for 12 weeks. Research-context cycles typically mirror this duration, though no published data guides cycling or extended use.
Important
Individual Response Varies
No human dose-response data exists for injectable AOD 9604. All dosage information is derived from oral clinical trials or community convention and should not be interpreted as medical guidance.
Safety & Information
AOD 9604 Safety Information
AOD 9604 is not FDA-approved as a drug. The FDA has evaluated AOD 9604-related bulk drug substances and found that available safety data is insufficient to support compounding for injectable use.
Important Safety Information
AOD 9604 is not a component of any FDA-approved drug product, and there is no United States Pharmacopeia (USP) monograph for the substance. The FDA has expressed concerns about the lack of adequate characterization data for AOD 9604, including potential peptide impurities, aggregates, and stability information for injectable formulations.
Human clinical trials using oral AOD 9604 reported serious adverse events including diarrhea, chest tightness, and various types of cancers. However, these trials did not evaluate the subcutaneous route commonly referenced in non-medical contexts.
Important
Non-Medical Use
AOD 9604 is marketed as a research peptide and has been detected in confiscated vials from athletes. It is on the World Anti-Doping Agency (WADA) Prohibited List under section S2.2. Non-medical use falls outside approved indications.
Potential Adverse Effects
In human clinical trials using oral AOD 9604, reported adverse events included diarrhea, chest tightness, and various types of cancers. Intravenous administration was associated with feeling of chest tightness and euphoria.
For injectable use, the FDA has noted concerns about potential immunogenicity due to peptide aggregation and impurities, as well as insufficient information to assess long-term safety.
Conditions Requiring Medical Evaluation
Given the absence of comprehensive human safety data for injectable use, any consideration of AOD 9604 should involve consultation with a qualified healthcare professional. The FDA has noted that obesity is a chronic condition potentially requiring long-term treatment, and there is insufficient information to support long-term safety.
Monitoring During Use
No established monitoring protocol exists for injectable AOD 9604. Published human trials using oral AOD 9604 monitored fasting glucose, IGF-1, and metabolic parameters, finding no significant effects at tested doses.
Product Care
Storage & Handling
Store lyophilized powder sealed and protected from light and moisture. Once reconstituted, store refrigerated at 2-8°C and use within 28 days. Do not freeze reconstituted solution. Keep out of reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
AOD 9604 5 mg is supplied through the official Peptide Hubs distribution chain and shipped in original manufacturer packaging with discreet handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official Peptide Hubs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your AOD 9604 5 mg product, use the security code on the vial label and cross-check it on the Peptide Hubs official site. Original packaging and manufacturer presentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
AOD 9604 5 mg Storage
Proper storage conditions help preserve peptide stability and integrity throughout shelf life.
Recommended Conditions
Store lyophilized powder sealed and protected from light and moisture. For longer-term storage, freezing at -20°C in a desiccated container is recommended.
Once reconstituted, store refrigerated at 2-8°C and use within 28 days. Do not freeze reconstituted solution. Protect from light and avoid exposure to strong reducing agents that could break the disulfide bond.
Keep out of reach of children. Follow proper handling practices.
Quick Reference
Do & Don't
- Do store powder sealed and protected from light
- Do keep in original packaging until use
- Do refrigerate reconstituted solution at 2-8°C
- Don't freeze reconstituted solution
- Don't expose to excessive heat or moisture
- Don't use if solution appears cloudy or contains particles
Frequently Asked Questions
AOD 9604 5 mg FAQ
Answers to common questions about AOD 9604 5 mg, hGH fragment peptides, and research compound handling.
What is AOD 9604 5 mg used for?
AOD 9604 5 mg contains a synthetic fragment of human growth hormone studied for its potential lipolytic activity. It was investigated in clinical trials for obesity treatment but failed to achieve significant weight loss in its pivotal trial. In non-medical bodybuilding contexts, it is commonly referenced for fat-loss support, though such use falls outside approved indications.
How often should AOD 9604 5 mg be injected?
Published human clinical trials used oral AOD 9604 once daily. For injectable use, community protocols commonly reference once-daily subcutaneous injections in a fasted state, though no published human trials have validated this route or schedule.
Does AOD 9604 5 mg require PCT?
AOD 9604 does not suppress endogenous testosterone production and does not require post-cycle therapy in the way anabolic steroids do. Its mechanism does not involve the hGH receptor or IGF-1 axis.
What does AOD 9604 do?
AOD 9604 is a fragment of human growth hormone that preclinical studies suggest stimulates lipolysis and fat oxidation without interacting with the hGH receptor. Unlike full-length GH, it does not raise IGF-1 or affect blood glucose levels in studied doses.
How long does AOD 9604 take to work?
AOD 9604 has a short plasma half-life of approximately 30 minutes following subcutaneous administration. Human clinical trials ran for 12-24 weeks, though the compound failed to demonstrate statistically significant weight loss.
Is AOD 9604 the best fat-loss peptide?
There is no universally “best” fat-loss peptide, and AOD 9604’s pivotal clinical trial failed to demonstrate significant efficacy. GLP-1 receptor agonists such as semaglutide and tirzepatide have demonstrated far greater weight loss in clinical trials.
What is the difference between AOD 9604 5 mg and Adipotide (FTPP)?
AOD 9604 is an hGH fragment studied for lipolytic activity through metabolic pathways, while Adipotide (FTPP) is a vascular-targeting peptidomimetic designed to induce apoptosis in adipose tissue vasculature. They operate through entirely different mechanisms and carry different risk profiles.
What is the difference between AOD 9604 5 mg and Sermorelin?
AOD 9604 is a fragment of the growth hormone molecule itself and does not stimulate GH release, while Sermorelin is a GHRH analog that stimulates endogenous GH production through pituitary receptors. They act through fundamentally different mechanisms.
Is 300 mcg of AOD 9604 a lot?
300 mcg falls within the range commonly referenced in research protocols (250-500 mcg per day), though no published human trial has validated injectable AOD 9604 at any dose. Oral clinical trial doses were substantially higher (1 mg per day) but used a different route.
What strength is AOD 9604 5 mg?
AOD 9604 5 mg is labeled at 5 mg of AOD 9604 per vial. It is supplied as a lyophilized powder in a 2 mL vial.
How should AOD 9604 5 mg be stored?
Store the lyophilized powder sealed and protected from light and moisture. Once reconstituted, refrigerate at 2-8°C and use within 28 days. Do not freeze reconstituted solution.
Related Offers
Lab Tested
Shipped International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Semax Synthetic ACTH(4-10) analogue heptapeptide
10 mg/vialStrength 10 mg/vial
Package 1 Vial 2 mL vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$42.00
$70.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance MOTS-c Mitochondrial-derived peptide (16 amino acids)
10 mg/vialStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$40.80
$68.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance GHK-CU Copper Tripeptide-1 (Glycyl-L-Histidyl-L-Lysine Copper)
50 mg/vialStrength 50 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$27.00
$45.00